# Somatostatin analogues (octreotide, lanreotide)

Source: https://onco.cc/drugs/octreotide-lanreotide/  
OnCo record `octreotide-lanreotide` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Monthly injections of a synthetic hormone that both quiets tumour hormone symptoms and slows tumour growth, the first treatment for most neuroendocrine tumours.

## Summary

Octreotide (1988) controls carcinoid syndrome; PROMID (2009) showed octreotide LAR delays progression in midgut NETs (TTP 14.3 vs 6.0 months); CLARINET (2014) showed lanreotide improves PFS across enteropancreatic NETs (median not reached vs 18 months, HR 0.47). Standard first-line antiproliferative therapy for SSTR-positive grade 1-2 disease; also premedication against carcinoid crisis.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-07
- Also known as: Octreotide; Lanreotide; Octreotide LAR; Somatostatin analogue
- Brand: Sandostatin LAR, Somatuline Depot
- Modality: Peptide hormone analogue (SSTR2 agonist)
- Mechanism: SSTR2/5 agonism suppresses hormone secretion and proliferation; PROMID and CLARINET established the antiproliferative effect.
- Approvals: US 1988: Carcinoid syndrome symptoms (octreotide); US 2014: Unresectable GEP-NETs to improve PFS (lanreotide)
- Dosing: Deep subcutaneous or intramuscular depot; Octreotide LAR 30 mg or lanreotide 120 mg every 4 weeks; short-acting octreotide for breakthrough symptoms

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Octreotide
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Somatostatin%20analogues

## Connected records

- cancers: [Cancer of unknown primary, favourable subsets](https://onco.cc/cancers/cup-favourable-subsets/), [Grade 3 well-differentiated neuroendocrine tumour](https://onco.cc/cancers/grade-3-net/), [Lung neuroendocrine tumours (typical and atypical carcinoid)](https://onco.cc/cancers/lung-net/), [Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)](https://onco.cc/cancers/multiple-endocrine-neoplasia/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Pancreatic neuroendocrine tumours](https://onco.cc/cancers/pancreatic-net/), [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/), [Small intestinal neuroendocrine tumours](https://onco.cc/cancers/small-intestinal-net/), [Thymoma (WHO types A, AB, B1, B2 and B3)](https://onco.cc/cancers/thymoma/), [Thymoma and thymic carcinoma](https://onco.cc/cancers/thymic-epithelial/)
- targets: [SHP2 (PTPN11)](https://onco.cc/targets/shp2/), [Somatostatin receptor 2](https://onco.cc/targets/sstr2/)
- companies: [Ipsen](https://onco.cc/companies/ipsen/), [Novartis](https://onco.cc/companies/novartis/)
- terms: [Carcinoid syndrome and carcinoid heart disease](https://onco.cc/terms/carcinoid-syndrome/), [PRRT (peptide receptor radionuclide therapy)](https://onco.cc/terms/prrt-term/)
- trials: [CLARINET](https://onco.cc/trials/clarinet/), [Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients](https://onco.cc/trials/nct00383708/), [Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula](https://onco.cc/trials/nct06807437/), [NETTER-1](https://onco.cc/trials/netter-1/), [PROMID](https://onco.cc/trials/promid/), [Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly](https://onco.cc/trials/nct00600886/), [SPINET](https://onco.cc/trials/spinet/)
- drugs: [Paltusotine](https://onco.cc/drugs/paltusotine/), [Pasireotide](https://onco.cc/drugs/pasireotide/), [Pegvisomant](https://onco.cc/drugs/pegvisomant/), [Telotristat ethyl](https://onco.cc/drugs/telotristat-ethyl/)

---
JSON: https://onco.cc/api/v1/entities/octreotide-lanreotide.json